Editas Medicine, Inc. (NASDAQ:EDIT) is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.64 per share from revenue of $ 6.36 million.
Looking ahead, the full year loss are expected at $ 2.53 per share on the revenues of $ 27.88 million.
Previous Quarter Performance
Editas Medicine, Inc. posted loss for the second quarter of $ 0.43 per share, from the revenue of $ 10.75 million. The quarterly revenues gained 361.37 percent compared with the same quarter last year. Street analysts expected Editas Medicine, Inc. to report loss of $ 0.79 per share on revenue of $ 6.34 million for the second quarter. The bottom line results beat street analysts by $ 0.36 or 45.57 percent, at the same time, top line results outshined analysts by $ 4.41 million or 69.56 percent.
Stock Performance
Shares of Editas Medicine, Inc. traded up $ 2.14 or 7.56 percent on Wednesday, reaching $ 30.45 with volume of 1.11 million shares. Editas Medicine, Inc. has traded high as $ 31.17 and has cracked $ 28.59 on the downward trend
The closing price of $ 30.45, representing a 102.07 % increase from the 52 week low of $ 14.01 and a 29.15 % decrease over the 52 week high of $ 39.96.
The company has a market capital of $ 1.90 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 31.00 target price.
Conference Call
Editas Medicine, Inc. will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.editasmedicine.com
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases.
